Zynerba Pharmaceuticals, Inc. (ZYNE)
| Market Cap | 134.54M |
| Revenue (ttm) | 86,000 |
| Net Income (ttm) | -52.43M |
| Shares Out | 29.24M |
| EPS (ttm) | -2.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $4.50 |
| Previous Close | $4.46 |
| Change ($) | 0.04 |
| Change (%) | 0.78% |
| Day's Open | 4.49 |
| Day's Range | 4.29 - 4.74 |
| Day's Volume | 1,565,357 |
| 52-Week Range | 2.55 - 9.00 |
ZYNE stock is on a roll, with investors betting its transdermal therapeutic cannabidiol gel will take off soon. The post ZYNE Stock: Why Zynerba Pharmaceutical Shares Are Soaring Today appeare...
DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ne...
- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -
DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Zynerba Pharmaceuticals, Inc. (ZYNE)
LOS ANGELES--(BUSINESS WIRE)---- $ZYNE #classaction--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Zynerba Pharmaceuticals (“Zynerba” or ...
- New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 -
DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and we will look ahead at the pot stocks to w...
Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) consolidated net revenue of CA$67.8 million ($52.3 million) for the first quarter of fiscal 2021, being up by around CA$300,000 from the fourth quarte...
DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...
Zynerba failed a phase 3 study using Zygel to treat the entire Fragile X syndrome population. However, the path forward remains targeting those with methylation of the FMR1 gene. An FDA meetin...
DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...
DEVON, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...
DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...
DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and nea...
Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients
Pivotal results from Phase 3 clinical trials of Zygel for the treatment of FX Syndrome didn’t meet endpoints, but a significant discovery was made.
Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ...
- Meeting with the U.S. Food and Drug Administration (FDA) Planned for 4Q2020 to Discuss the Regulatory Path Forward for Zygel™ in Children and Adolescents with Fragile X Syndrome and a Fully ...
DEVON, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ...
Exploring more about medical/pharma side of cannabis sector and thematic ETF investing.
DEVON, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and n...
DEVON, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and n...
Pharma Medical Cannabis More Robust And Resilient (Podcast)
Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.79, moving +1.34% from the previous trading session.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
- New Data Show Statistically Significant Improvements in Caregiver Impression of Change in Fragile X Behaviors Including Social Avoidance in Patients with Fully Methylated FMR1 genes - - New ...
Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
Zynerba's (ZYNE) shares plunge 48.5% following the study data readout, which demonstrated failure to achieve statistical significance in primary endpoint.
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares retreated to their lowest level since early April following a clinical readout from the company.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) has disclosed that its cannabis-based gel did not see statistically significant results from its most recent study.
- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set -
Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.
The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?
The 2020 year is practically halfway done, and this has really been the year of the biotech.
The stock market’s fall from February through March was monumental, bringing on the fastest bear market we have seen in our lives.
- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist -
- Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial -
DEVON, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and ne...
Is (ZYNE) Outperforming Other Medical Stocks This Year?
Zynerba Pharmaceuticals (ZYNE) closed the most recent trading day at $3.47, moving +1.76% from the previous trading session.
- New Data Presented Today at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting - - New Data Presented Today at the American Society for Experimental Neurotherapeuti...
Zynerba Pharmaceuticals (ZYNE) closed at $4.18 in the latest trading session, marking a -1.88% move from the prior day.
Topline Results are expected late in the Second Quarter of 2020 Topline Results are expected late in the Second Quarter of 2020
DEVON, Pa., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and n...
Zynerba Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Company Expects to Complete Randomization in February 2020 -
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $5.70, marking a -0.35% move from the previous day.
About ZYNE
Zynerba Pharmaceuticals operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder; is in Phase II clinical... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Aug 5, 2015 |
| CEO Armando Anido | Employees 28 |
| Stock Exchange NASDAQ | Ticker Symbol ZYNE |
Analyst Forecasts
According to 7 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is 7.25, which is an increase of 61.29% from the latest price.